9-50岁健康个体采用替代初免疫程序后接种CYD-TDV登革热疫苗加强针的免疫原性与安全性:一项随机、对照、2期、非劣效性研究
在哥伦比亚和菲律宾6个中心纳入1050名9-50岁健康个体,随机接受三剂、两剂或一剂CYD-TDV初免疫程序,并随机在末剂后1年或2年接种加强针。在基线登革血清阳性的哥伦比亚队列中,两剂或三剂初免后1年或2年加强针未在所有四个血清型中显示非劣效性,未发现安全性问题。
要点
- 三剂初免后1年加强针仅对血清型2和3显示非劣效,对血清型1和4未显示。
- 两剂初免后1年加强针仅对血清型2和3显示非劣效,对血清型1和4未显示。
- 1年或2年CYD-TDV加强针未报告安全性问题。
核心结论
- 两剂或三剂初免后1年或2年接种CYD-TDV加强针,在基线登革血清阳性参与者中未对所有登革血清型引出持续、有意义的加强效应。
研究设计与样本
- 随机、对照、2期、非劣效性研究,从哥伦比亚3个中心和菲律宾3个中心招募9-50岁健康个体,随机分配接受三剂、两剂或一剂CYD-TDV初免疫程序,并随机在末剂后1年或2年接种加强针。
主要发现
- 三剂初免后1年加强针:血清型2 GMR 0.746(95%CI 0.550-1.010)和血清型3 GMR 1.040(95%CI 0.686-1.570)显示非劣效,血清型1 GMR 0.567(95%CI 0.399-0.805)和血清型4 GMR 0.647(95%CI 0.434-0.963)未显示非劣效。
- 三剂初免后2年加强针:血清型2 GMR 0.871(95%CI 0.673-1.130)和血清型3 GMR 1.150(95%CI 0.887-1.490)显示非劣效,血清型1 GMR 0.688(95%CI 0.479-0.989)和血清型4 GMR 0.655(95%CI 0.471-0.911)未显示非劣效。
- 两剂初免后1年加强针:血清型2 GMR 0.809(95%CI 0.505-1.300)和血清型3 GMR 1.19(95%CI 0.732-1.940)显示非劣效,血清型1 GMR 0.627(95%CI 0.342-1.150)和血清型4 GMR 0.499(95%CI 0.331-0.754)未显示非劣效。
- 两剂初免后2年加强针:血清型3 GMR 0.911(95%CI 0.573-1.450)显示非劣效,血清型1 GMR 0.889(95%CI 0.462-1.710)、血清型2 GMR 0.677(95%CI 0.402-1.140)和血清型4 GMR 0.702(95%CI 0.447-1.100)未显示非劣效。
- 1年或2年CYD-TDV加强针未报告安全性问题。
关键数值与推荐
- 非劣效性标准:组间几何平均比(GMR)的双侧校正95%CI下限高于0.5,每个血清型均需满足。
- 三剂初免组108例、两剂初免组115例、一剂初免组115例基线登革血清阳性者接受了加强针。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于研究方案变更,仅哥伦比亚队列中基线登革血清阳性的参与者接受了加强针。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue is endemic in many countries throughout the tropics and subtropics, and the disease causes substantial morbidity and health-care burdens in these regions. We previously compared antibody responses after one-dose, two-dose, or three-dose primary regimens with the only approved dengue vaccine CYD-TDV (Dengvaxia; Sanofi Pasteur, Lyon, France) in individuals aged 9 years and older with previous dengue exposure. In this study, we assessed the need for a CYD-TDV booster after these primary vaccination regimens. METHODS: In this randomised, controlled, phase 2, non-inferiority study, healthy individuals aged 9-50 years recruited from three sites in Colombia and three sites in the Philippines (excluding those with the usual contraindications to vaccinations) were randomly assigned 1:1:1 via a permuted block method with stratification by site and by age group using an independent voice response system to receive, at 6-month intervals, three doses of CYD-TDV (three-dose group), one dose of placebo followed by two doses of CYD-TDV (two-dose group), or two doses of placebo followed by one dose of CYD-TDV (one-dose group). Participants were also randomly assigned (1:1) to receive a CYD-TDV booster at 1 year or 2 years after the last primary dose. Each CYD-TDV dose was 0·5 mL and administered subcutaneously in the deltoid region of the upper arm. The investigators and sponsor, study staff interacting with the investigators, and participants and their parents or legally acceptable representatives were masked to group assignment. Neutralising antibodies were measured by 50% plaque reduction neutralisation testing, and geometric mean titres (GMTs) were calculated. Due to a change in study protocol, only participants who were dengue seropositive at baseline in the Colombian cohort received a booster vaccination. The primary outcome was to show non-inferiority of the booster dose administered at 1 year or 2 years after the two-dose and three-dose primary regimens; non-inferiority was shown if the lower limit of the two-sided adjusted 95% CI of the between-group (day 28 post-booster dose GMT from the three-dose or two-dose group vs day 28 GMT post-dose three of the three-dose primary regimen [three-dose group]) geometric mean ratio (GMR) was higher than 0·5 for each serotype. Non-inferiority of the 1-year or 2-year booster was shown if all four serotypes achieved non-inferiority. Safety was assessed among all participants who received the booster. This trial is registered with ClinicalTrials.gov, NCT02628444, and is closed to accrual. FINDINGS: Between May 2 and Sept 16, 2016, we recruited and enrolled 1050 individuals who received either vaccine or placebo. Of the 350, 348, and 352 individuals randomly assigned to three-dose, two-dose, and one-dose groups, respectively, 108, 115, and 115 from the Colombian cohort were dengue seropositive at baseline and received a booster; 55 and 53 in the three-dose group received a booster after 1 year and 2 years, respectively, as did 59 and 56 in the two-dose group, and 62 and 53 in the one-dose group. After the three-dose primary schedule, non-inferiority was shown for serotypes 2 (GMR 0·746; 95% CI 0·550-1·010) and 3 (1·040; 0·686-1·570) but not serotypes 1 (0·567; 0·399-0·805) and 4 (0·647; 0·434-0·963) for the 1-year booster, and again for serotypes 2 (0·871; 0·673-1·130) and 3 (1·150; 0·887-1·490) but not serotypes 1 (0·688; 0·479-0·989) and 4 (0·655; 0·471-0·911) for the 2-year booster. Similarly, after the two-dose primary schedule, non-inferiority was shown for serotypes 2 (0·809; 0·505-1·300) and 3 (1·19; 0·732-1·940) but not serotypes 1 (0·627; 0·342-1·150) and 4 (0·499; 0·331-0·754) for the 1-year booster, and for serotype 3 (0·911; 0·573-1·450) but not serotypes 1 (0·889; 0·462-1·710), 2 (0·677; 0·402-1·140), and 4 (0·702; 0·447-1·100) for the 2-year booster. Thus, non-inferiority of the 1-year or 2-year booster was not shown after the three-dose or two-dose primary vaccination regimen in dengue-seropositive participants. No safety concerns occurred with the 1-year or 2-year CYD-TDV booster. INTERPRETATION: CYD-TDV booster 1 year or 2 years after the two-dose or three-dose primary vaccination regimen does not elicit a consistent, meaningful booster effect against all dengue serotypes in participants who are seropositive for dengue at baseline. FUNDING: Sanofi Pasteur. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.
引用
- Coronel-Martinez DL, Park J, López-Medina E, et al. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study. Lancet Infect Dis. 2022. PMID: 35364022. doi:10.1016/S1473-3099(21)00706-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。